<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00506961</url>
  </required_header>
  <id_info>
    <org_study_id>AZ-RSV-RT-01</org_study_id>
    <nct_id>NCT00506961</nct_id>
  </id_info>
  <brief_title>Evaluate the Efficacy and Safety of Rosuvastatin Versus Simvastatin in Type 2 Diabetic Patients With Dyslipidemia</brief_title>
  <official_title>A Phase IV, Randomized, Open-label, Parallel-arm, Comparative and Forced- Titration Study to Compare the Efficacy and Safety of Rosuvastatin Versus Simvastatin in Patients With Type 2 DM and Dyslipidemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taipei Veterans General Hospital, Taiwan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taipei Veterans General Hospital, Taiwan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase IV, randomized, open-label, parallel-arm, comparative and forced- titration
      study to compare the efficacy and safety of rosuvastatin versus simvastatin in patients with
      type 2 DM and dyslipidemia. When comparing the efficacy of rosuvastatin 20 mg with
      simvastatin 40 mg for the treatment of type 2 DM with dyslipidemia, rosuvastatin 20 mg is
      superior to simvastatin 40 mg in achieving the combined goal of LDL-C (&lt;100 mg/dL) and
      non-HDL-C (&lt;130 mg/dL).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The duration of patient participation will be 18 weeks consisting of a 1-week screening
      period, a 5-week lead-in period, followed by a 12-week treatment period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">July 2007</completion_date>
  <primary_completion_date type="Actual">July 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The percentage of patients achieving the combined treatment goal of LDL-C &lt; 100mg/dl and non-HDL-C &lt; 130 mg/dl at week 12 with rosuvastatin treatment compared with simvastatin treatment</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Achieving the combined treatment goal of LDL-C (&lt;100 mg/dL) and non-HDL-C (130 mg/dL) at week 4;</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients achieving the LDL-C goal of &lt;100 mg/dL at week 4 and week 12;</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients achieving the LDL-C goal of ＜70 mg/dL at Week;The mean percent change from baseline in lipid profile at week 4 and week 12;</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Diabetes Mellitus</condition>
  <condition>Dyslipidemia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 mg rosuvastatin for 4 weeks followed by 20 m rosuvastatin for another 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 mg simvastatin for 4 weeks followed by 40 mg simvastatin for another 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>10 mg rosuvastatin for 4 weeks followed by rosuvastatin or another 12 weeks</description>
    <arm_group_label>1</arm_group_label>
    <other_name>crestor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin</intervention_name>
    <description>20 mg simvastatin for 4 weeks followed by 40 mg simvastatin for another 8 weeks</description>
    <arm_group_label>2</arm_group_label>
    <other_name>zocor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and female between the ages of 20-75 years.

          2. Female patients post menopausal, hysterectomized or if of childbearing potential using
             a reliable method of birth control.

          3. Diagnosed with type 2 diabetes mellitus.

          4. Fasting triglyceride ≧150 mg/dL ≦500 mg/dL or Non-HDL-C≧130,but≦200 mg/dL

          5. Patients receiving stable antidiabetic treatment for 8 weeks before randomization (no
             change in the category of anti-diabetic agents, but the dose is adjustable).

          6. All patients give written informed consent.

        Exclusion Criteria:

          1. A history of hypersensitivity to statins.

          2. A history of rhabdomyolysis or hereditary muscle disorders.

          3. Insulin-treated patients.

          4. Patient with any conditions of acute or chronic pancreatitis.

          5. Creatine kinase ≧3-fold upper limit of normal (ULN).

          6. Patients with an estimated creatinine clearance (see note)≦30 ml/min or bilirubin
             ≧1.5-fold ULN, or chronic active hepatitis or liver function impairment (AST and ALT
             ≧3-fold ULN).

          7. Overt proteinuria (repeat spot urine protein &gt;300mg/dl by dipstick method).

          8. Patients are taking cyclosporine.

          9. A history of homozygous familial hypercholesterolemia or familial
             dysbetalipoproteinemia.

         10. Patients with alcohol and drug abuse in past 3 years.

         11. Serious or unstable medical or psychological conditions.

         12. Hypothyroidism (TSH &gt; 5 μIU/mL).

         13. In the investigator's opinion, continuation in the study would be detrimental to the
             patient's well-being or might confound the clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chii-Min Hwu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Taipei Veterans General Hospital, Taiwan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wayne H Sheu, MD,phD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Taichung Veterans General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 24, 2007</study_first_submitted>
  <study_first_submitted_qc>July 24, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 25, 2007</study_first_posted>
  <last_update_submitted>December 5, 2011</last_update_submitted>
  <last_update_submitted_qc>December 5, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 6, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Taipei Veterans General Hospital, Taiwan</investigator_affiliation>
    <investigator_full_name>vghtpe user</investigator_full_name>
    <investigator_title>Attending physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

